These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 24233123

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Are there any positive effects of TNF-alpha blockers on bone metabolism?].
    Seriolo B, Paolino S, Sulli A, Cutolo M.
    Reumatismo; 2006 Mar; 58(3):199-205. PubMed ID: 17013436
    [Abstract] [Full Text] [Related]

  • 6. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
    Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, Han KH, Breedveld FC, Dijkmans BA, Allaart CF, Lems WF.
    Ann Rheum Dis; 2008 Jun; 67(6):823-8. PubMed ID: 17644545
    [Abstract] [Full Text] [Related]

  • 7. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.
    Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R, Denosumab RA Study Group.
    Ann Rheum Dis; 2010 May; 69(5):872-5. PubMed ID: 19734132
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNFα therapy and discontinuation of glucocorticoids.
    Brabnikova Maresova K, Jarosova K, Pavelka K, Stepan JJ.
    Rheumatol Int; 2013 Aug; 33(8):2001-7. PubMed ID: 23370856
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study.
    Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Koike T.
    Rheumatol Int; 2018 May; 38(5):777-784. PubMed ID: 29294175
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis.
    Chen JF, Hsu CY, Yu SF, Ko CH, Chiu WC, Lai HM, Chen YC, Su YJ, Cheng TT.
    Rheumatology (Oxford); 2020 Sep 01; 59(9):2471-2480. PubMed ID: 31984422
    [Abstract] [Full Text] [Related]

  • 14. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials.
    Siu S, Haraoui B, Bissonnette R, Bessette L, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Kraft J, Lynde C, Gulliver W, Keeling S, Dutz J, Pope JE.
    Arthritis Care Res (Hoboken); 2015 May 01; 67(6):754-64. PubMed ID: 25418272
    [Abstract] [Full Text] [Related]

  • 15. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
    Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP.
    Ann Rheum Dis; 2009 Mar 01; 68(3):373-6. PubMed ID: 18408246
    [Abstract] [Full Text] [Related]

  • 16. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov 01; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 17. Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids.
    Matsuno H.
    Drugs R D; 2016 Dec 01; 16(4):347-353. PubMed ID: 27766589
    [Abstract] [Full Text] [Related]

  • 18. Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study.
    Tada M, Inui K, Sugioka Y, Mamoto K, Okano T, Anno S, Koike T.
    Rheumatol Int; 2017 Jun 01; 37(6):999-1005. PubMed ID: 28405825
    [Abstract] [Full Text] [Related]

  • 19. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
    Chen YM, Chen HH, Huang WN, Liao TL, Chen JP, Chao WC, Lin CT, Hung WT, Hsieh CW, Hsieh TY, Chen YH, Chen DY.
    PLoS One; 2017 Jun 01; 12(11):e0188454. PubMed ID: 29155868
    [Abstract] [Full Text] [Related]

  • 20. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y, Suzuki T, Kato H.
    Arch Osteoporos; 2017 Sep 21; 12(1):80. PubMed ID: 28936606
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.